ClinicalTrials.gg
RecruitingNCT07866846PasiAcroKetoUpdated Oct 8, 2026

Managing Pasireotide-associated Hyperglycaemia in Acromegaly With Ketogenic Diet

An interventional study of Ketogenic diet and Diabetes Medication in Acromegaly Due to Pituitary Adenoma, Hyperglycemia and Ketogenic Diet, sponsored by Leiden University Medical Center. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Leiden University Medical Center · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 11 months after the study started (first participant enrolled Jul 2025, registered Jul 2026).
  • Started Jul 2025; still recruiting 1 year 3 months later.
Updated Oct 8, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Hyperglycemia with a site in Netherlands — 2 open to participants now, 2 under way, none of them phase 3. Hyperglycemia · Netherlands.

Planned enrollment
11th of 14
30 · median 91
Started
2025
the only one that year
No phase
10 of 15
2 open now
Registered
15th of 15
by date
Lead sponsor
1 of 15
Leiden University Medical Center

Among the 15 studies in Hyperglycemia with a site in Netherlands, this one is the 11th largest by planned enrollment of the 14 interventional ones that give a count, is the only one that started in 2025, is one of 10 with no phase, and was the 15th registered.

Hyperglycemia

802 studies on the registry are indexed under Hyperglycemia; 115 are open to participants now.

Browse Hyperglycemia studies →

Open to participants now

2 of the 15 studies in Hyperglycemia with a site in Netherlands are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 71 Hyperglycemia studies recruiting now, 42 (59%) set no upper age limit and 23 (32%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Hyperglycemia with a site in Netherlands, or all of them as a file.
02

Study summary

Rationale: Pasireotide is a second line medical treatment for acromegaly that can add value for patients with insufficient control of disease on 1st generation SRL, or 1st generation SRL + pegvisomant. A well-known advserse effect of pasireotide is development of hyperglycemia in 50-70% of cases. Eucaloric very-low carbohydrate ketogenic diet (VLCKD) improves hemoglobin a1c (HbA1c) and fasting plasma glucose (FPG) levels and can show even a long-term effect on glucose regulation in patients with acromegaly. Moreover, the eucaloric VLCKD has improved disease control in patients with acromegaly.

Objective: The primary objective of this study is to evaluate the change in HbA1c from start of intervention (baseline of the core study) to post-four months of ketogenic diet compared to standard of care (core study) in patients developing pasireotide-induced hyperglycemia.The secondary objectives are to evaluate:

  • Differences between eucaloric very-low carbohydrate ketogenic diet and standard of care (diabetes medication) regarding:

    • Proportion of patients with target HbA1c (\<48mmol/L / \<6.5%) achieved without glucose lowering drugs (beyond metformine monotherapy) in both arms
    • Evaluation and sustainability of glycaemic control (HbA1c) and (dosage of) anti-diabetic drugs need to reach control
    • Biochemical control, and symptom score of acromegaly
    • Quality of life
    • Proportion of patients on 40 and 60 mg, proportion with normal IGF-1, tolerability, and safety of pasireotide
  • Exploratory evaluation of all eligible subjects considered for and started with pasireotide treatment to get a better insight into these complicated acromegaly patients and their metabolic profile.
  • Exploratory evaluation of other timepoints (start of pasireotide) to analyse course of Hba1c development from start of pasireotide until the end of the core study Study design: Study type: multicenter combined observational and interventional randomized controlled study. Allocation: randomized (1:1 ratio). Intervention model: parallel assignment. Masking: non (open-label). Primary purpose: supportive care.

Study population: Adult patients with a confirmed diagnosis of acromegaly (for whom surgery is not an option, or for whom surgery has failed) and with inadequately GH and/or IGF-1 control (>0.8xULN) or active disease symptoms with first-generation SRL, or with inadequately GH and/or IGF-1 control (>0.8xULN) or active disease symptoms on second-line medical treatments for acromegaly (pegvisomant monotherapy or combination therapy with first-generation SRL and pegvisomant or dopamine agonist, respectively) and with a baseline Hba1c \<44 mmol/L (6.2%) - including those pre-treated with metformin in case of HbA1c ≥44 mmol/L (6.2%) and ≤64 mmol/L (8.0%) - in whom pasireotide is considered in the clinical setting.

Intervention (if applicable): We aim to include 30 acromegaly patients with pasireotide-induced hyperglycaemia, to ensure that 20 patients complete the 4-month intervention. Subjects will be randomized 1:1 to open-label eucaloric very-low carbohydrate ketogenic diet (\<40 g of carbohydrate) or standard of care (i.e. metformin, followed by sitagliptin (DPP4-inhibitor), incretin-based therapy with liraglutide (GLP-1 receptor agonist), and insulin) at the time hyperglycemia is present. The randomized intervention period is 4 months (core phase of the study). Randomized subjects who reach the end of the randomized phase can continue with the open-label extension, and opt to continue their randomized diet or DM drug treatment or freely choose the other alternative for another 4 months (extension study).

Main study parameters/endpoints:

Evaluation of effect of treatment with eucaloric very-low carbohydrate ketogenic diet or diabetes medication on glycaemic control of pasireotide:

- Change in HbA1c from start core study to the end of the intervention (ketogenic diet vs standard of care) Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Study participants will have 8 visits to the outpatient clinic over a period of 12-15 months. This comes down to 480 minutes in total. During these visits, physical exam/anthropometric measurements will be performed and 2 blood tubes of 2,5 cc will be collected and 3 QoL questionnaires and one food diary will be filled out (total visit: 60 minutes). The usual burden for a single patient is 3-outpatient visits over a period of 1 year, which takes about 60 minutes in total and with the same volume of blood per visit.

03

Conditions studied

  • Acromegaly Due to Pituitary Adenoma
  • Hyperglycemia
  • Ketogenic Diet
  • Standard Care Control

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All patients with acromegaly eligible for inclusion are patients in whom pasireotide is considered in the clinical setting.

  • Adult patients with a confirmed diagnosis of acromegaly (for whom surgery is not an option, or for whom surgery has failed) and with either inadequately GH and/or IGF-1 control (>0.8xULN) or active disease symptoms with first-generation SRL, or with inadequately GH and/or IGF-1 control (>0.8xULN) or active disease symptoms on medical treatments for acromegaly (pegvisomant monotherapy or combination therapy with first-generation SRL and pegvisomant or dopamine agonist, respectively), and with a baseline \<44 mmol/L (6.2%).
  • Adult patients with a confirmed diagnosis of acromegaly (for whom surgery is not an option, or for whom surgery has failed) and with either inadequately GH and/or IGF-1 control (>0.8xULN) or active disease symptoms with first-generation SRL, or with inadequately GH and/or IGF-1 control (>0.8xULN) or active disease symptoms on second-line medical treatments for acromegaly (pegvisomant monotherapy or combination therapy with first-generation SRL and pegvisomant or dopamine agonist, respectively), and with a baseline Hba1c ≥44 mmol/L (6.2%) and ≤64 mmol/L (8.0%) which can first be treated and stabilized with metformine prior to rescreening and baseline measurement and are eligible if they achieve a Hba1c \<44 mmol/L (6.2%).

Because of the low incidence rate of acromegaly and pasireotide use, we can offer patients that are already on chronic treatment with pasireotide and develop newly onset diabetes the interventions. Moreover, as mentioned prior, patients excluded from the interventional study at any time can participate in the observational part of the study.

  • Age ≥18 years
  • Confirmed diagnosis of acromegaly (for whom surgery is not an option, or for whom surgery has failed) and with inadequately GH and/or IGF-1 control (>0.8xULN)

Exclusion criteria

Exclusion Criteria:

  • Has undergone pituitary surgery within 6 months prior to study entry;
  • Has undergone radiotherapy within 2 years prior to study entry;
  • Patients using pasireotide at screening.
  • Patients who have a to metformin, sitagliptin, liraglutide, or insulin.
  • Diabetes mellitus type 2 patients receiving diabetic medication other than metformin or with poor glycaemic control, defined as ≥9.0% (less stringent cut-off) at screening.
  • Diabetes mellitus type 1.
  • Life-threatening diabetic ketoacidosis or diabetic hyperosmolar coma.
  • It is anticipated that the patient receives pituitary surgery or radiotherapy during the study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Ketogenic diet

    After 3 months of pasireotide treatment, there is an evaluation of glycemic status and acromegalic biochemical control. Patients with hyperglycemia (Hba1c\>6.5% or \>48 mmol/L) will be randomized 1:1 to ketogenic diet or antidiabetic drug. An ad libitum ketogenic diet of which only the amount of carbohydrates is restricted (\<40 g of carbohydrate, approximately 155 g of fat, and approximately 115 g of protein per day). This amount of carbohydrates will lead to ketogenesis.

    Dietary Supplement: Ketogenic diet

  • Active comparator
    Antidiabetic drugs, standard care

    Subjects randomized to the diabetes medication arm will be treated with diabetic drugs according to the current Dutch guidelines, and the recently published consensus statement for the treatment of pasireotide-induced hyperglycemia.

    Drug: Diabetes Medication

Interventions

  • Dietary supplementKetogenic diet

    Subjects randomized to the eucaloric very-low carbohydrate ketogenic diet start with an ad libitum ketogenic diet of which only the amount of carbohydrates is restricted (\<40 g of carbohydrate, approximately 155 g of fat, and approximately 115 g of protein per day). This amount of carbohydrates will lead to ketogenesis. Emphasis is placed on the use of products high in polyunsaturated and monounsaturated fatty acids (diet margarines, oils, fish, nuts), preferably with vegetable and marine sources of protein, in concordance with the national nutritional guidelines and the Mediterranean diet (11). We aim for a eucaloric diet, not restricting energy intake. For women we aim at 2000 kcal/day, for men 2500 kcal/day.

  • DrugDiabetes Medication

    Subjects randomized to the diabetes medication arm will be treated with diabetic drugs according to the current Dutch guidelines, and the recently published consensus stategement for the treatment of pasireotide-induced hyperglycemia (outlined in Fig 2.) (22). Dose escalation or medication switches are made every 2-4 weeks at the discretion of the treating physician aiming at a normal Hba1c of \<44 mmol/L (Hba1c\<6.2%).

06

What researchers measure

Primary outcomes

  1. Hemoglobin A1c (HbA1c) level

    Glycaemic control will be assessed by measurement of HbA1c, expressed in mmol/mol. The outcome measure is the HbA1c value at each scheduled study assessment.

    Time frame: At baseline, and 3 months, 7 months, 9, 11 and 13 months after initiation of pasireotide treatment.

Secondary outcomes

  1. Dietary intake of energy

    Dietary intake assessed using a 3 days food diary. Total energy intake (kcal/day) will be quantified.

    Time frame: Baseline and at 3, 7, 9 and 13 month after initiation of pasireotide treatment.

  2. Dietary intake of carbohydrates

    Dietary intake assessed using a 3-day food diary. Carbohydrate intake will be quantified as absolute intake (g/day) and as a percentage of total energy intake (%E).

    Time frame: Baseline and at 3, 7, 9 and 13 month after initiation of pasireotide treatment.

  3. Dietary intake of proteins

    Dietary intake assessed using a 3-day food diary. Protein intake will be quantified as absolute intake (g/day) and as a percentage of total energy intake (%E).

    Time frame: Baseline and at 3, 7, 9 and 13 month after initiation of pasireotide treatment.

  4. Dietary intake of fat

    Dietary intake assessed using a 3-day food diary. Fat intake will be quantified as absolute intake (g/day) and as a percentage of total energy intake (%E).

    Time frame: Baseline and at 3, 7, 9 and 13 month after initiation of pasireotide treatment.

  5. Dietary intake of fiber

    Dietary intake assessed using a 3-day food diary. Fiber intake will be quantified as absolute intake (g/day).

    Time frame: Baseline and at 3, 7, 9 and 13 month after initiation of pasireotide treatment.

  6. Nutritional adequacy of the dietary pattern

    Dietary intake will be assessed using a 3-day food diary. Micro-nutrient intake will be quantified and compared with the Recommended Dietary Allowance (RDA) for micro-nutrients. Based on this comparison, the patient's dietary pattern will be classified as nutritionally adequate (yes/no).

    Time frame: Baseline and at 3, 7, 9 and 13 month after initiation of pasireotide treatment.

  7. Acromegaly Quality of Life Questionnaire (AcroQoL) score

    Quality of life will be assessed using the Acromegaly Quality of Life Questionnaire (AcroQoL), a disease-specific questionnaire consisting of 22 items evaluating physical and psychological aspects of quality of life. Responses are recorded on a 5-point Likert scale assessing frequency of occurrence (1 = always to 5 = never) or degree of agreement (1 = completely agree to 5 = completely disagree). The total AcroQoL score will be used as the outcome measure.

    Time frame: Baseline, 3 months, 7 months, 11 months and 13 months after start intervention.

  8. Hand grip strength

    Hand grip strength, expressed in kilograms (kg), measured using a hand dynamometer as an indicator of muscle strength and physical function.

    Time frame: Baseline and 3, 7, 9, 11, and 13 months after initiation of the intervention.

  9. Change in Patient-Assessed Acromegaly Symptom Questionnaire (PASQ) total score from baseline

    Change from baseline in acromegaly symptom burden assessed using the Patient-Assessed Acromegaly Symptom Questionnaire (PASQ). The PASQ evaluates five acromegaly-related symptoms (soft-tissue swelling, arthralgia, headache, excessive perspiration, and fatigue). Each symptom is scored from 0 to 8, with higher scores indicating greater symptom severity. The total PASQ score ranges from 0 to 40.

    Time frame: At start intervention, and 3, 7, 11 and 13 months after initiation.

  10. Height

    Standing height, expressed in meters (m), measured as part of the anthropometric assessment.

    Time frame: Baseline

  11. Body weight

    Body weight, expressed in kilograms (kg), measured as part of the anthropometric assessment.

    Time frame: Baseline, 3, 7, 9, 11 and 13 months after initiation of the intervention.

  12. Body Mass Index

    Body mass index (BMI), expressed in kg/m², calculated as body weight in kilograms divided by the square of height in meters (kg/m²). BMI is measured as part of the anthropometric assessment.

    Time frame: Baseline, 3, 7, 9, 11 and 13 months after initiation of the intervention.

  13. Fat-free mass

    Fat-free mass, including skeletal muscle mass, expressed in kilograms (kg), measured as part of the anthropometric assessment of the body composition.

    Time frame: Baseline and 3, 7, 9, 11, and 13 months after initiation of the intervention.

  14. Fat mass

    Body fat mass, expressed in kilograms (kg) and as a percentage of total body weight (%), measured as part of the anthropometric assessment.

    Time frame: Baseline and 3, 7, 9, 11, and 13 months after initiation of the intervention.

  15. Resting energy expenditure

    Resting energy expenditure (REE), expressed in kilocalories per day (kcal/day), measured to assess energy metabolism under resting conditions.

    Time frame: Baseline and 3, 7, 9, 11, and 13 months after initiation of the intervention.

  16. Insulin-like Growth Factor 1 (IGF-1) level

    Plasma insulin-like growth factor 1 (IGF-1) concentration, expressed in nmol/L, measured to assess biochemical disease control.

    Time frame: Baseline and 3, 7, 9, 11, and 13 months after initiation of the intervention.

  17. Growth hormone (GH) level

    Serum growth hormone (GH) concentration, expressed in µg/L, measured as a marker of biochemical control of acromegaly.

    Time frame: Baseline and 3, 7, 9, 11, and 13 months after initiation of the intervention.

  18. Fasting plasma glucose level

    Fasting plasma glucose concentration, expressed in mmol/L, measured after an overnight fast to assess glycaemic control.

    Time frame: Baseline and 3, 7, 9, 11, and 13 months after initiation of the intervention

  19. Fasting insulin in pmol/l

    Fasting insulin concentration, expressed in pmol/L, measured after an overnight fast to assess insulin secretion and metabolic status.

    Time frame: Baseline and 3, 7, 9, 11, and 13 months after initiation of the intervention.

  20. Total cholesterol level

    Total cholesterol concentration, expressed in mmol/L, measured to assess lipid metabolism and cardiovascular risk.

    Time frame: Baseline, 9 and 13 months after initiation of the intervention.

  21. High-density lipoprotein (HDL) cholesterol level

    High-density lipoprotein (HDL) cholesterol concentration, expressed in mmol/L, measured to assess lipid metabolism and cardiovascular risk profile.

    Time frame: Baseline, 9 and 13 months after initiation of the intervention.

  22. Low-density lipoprotein (LDL) cholesterol level Show more lines

    Low-density lipoprotein (LDL) cholesterol concentration, expressed in mmol/L, measured to assess lipid metabolism and cardiovascular risk profile.

    Time frame: Baseline, 9 and 13 months after initiation of the intervention.

  23. Triglyceride level

    Triglyceride concentration, expressed in mmol/L, measured to assess lipid metabolism and cardiovascular risk profile.

    Time frame: Baseline, 9 and 13 months after initiation of the intervention.

Other outcomes

  1. D-KETOcheck questionnaire score

    Adherence to the ketogenic diet will be assessed using the D-KETOcheck questionnaire in participants assigned to the ketogenic diet intervention. The questionnaire consists of 11 items evaluating adherence to and experiences with the ketogenic diet. Each item is scored on a 5-point scale from 0 to 4, with higher scores indicating stronger agreement with and adherence to the ketogenic diet. The total D-KETOcheck score will be used as the outcome measure.

    Time frame: Only for patients randomized to ketogenic diet; at 2 weeks, 8 weeks, 16 weeks and 32 weeks of ketogenic diet.

  2. Phase angle

    Phase angle, expressed in degrees (°), measured as part of the anthropometric assessment using bioelectrical impedance analysis (BIA). Phase angle is considered an indicator of cellular health, cell membrane integrity, and nutritional status.

    Time frame: Baseline and 3, 7, 9, 11, and 13 months after initiation of the intervention.

  3. Free fatty acid level

    Plasma free fatty acid concentration, expressed in mmol/L, measured as a marker of ketogenesis.

    Time frame: Samples will be collected at baseline, 9 and 13 months after start of the intervention, and stored for batched analysis at a later time point.

  4. Beta-hydroxybutyrate level

    Plasma beta-hydroxybutyrate concentration, expressed in mmol/L, measured as a marker of ketogenesis.

    Time frame: Baseline, 9 and 13 months after initiation of the intervention.

  5. Total body water percentage

    Total body water, expressed as a percentage of body weight (%), measured as part of the anthropometric assessment to evaluate changes in body fluid status and potential fluid retention (edema), which may influence fat-free mass measurements.

    Time frame: Baseline and 3, 7, 9, 11, and 13 months after initiation of the intervention.

  6. Proportion of participants receiving 40 mg or 60 mg pasireotide

    Proportion of participants treated with a monthly pasireotide dose of 40 mg or 60 mg during the study period. Dose adjustments are performed according to clinical practice and biochemical disease control of acromegaly.

    Time frame: Through study completion, an average of 1 year

  7. Proportion of participants with normalized insulin-like growth factor 1 (IGF-1) levels

    Proportion of participants with age- and sex-adjusted normal insulin-like growth factor 1 (IGF-1) levels, assessed as a marker of biochemical control of acromegaly.

    Time frame: Through study completion, an average of 1 year

  8. Proportion of participants discontinuing pasireotide due to adverse events

    Proportion of participants who permanently discontinue pasireotide treatment due to treatment-related adverse events or intolerance.

    Time frame: Through study completion, an average of 1 year

07

Study locations

1 of 1 sites recruiting
  • Leiden University Medical Centre
    Leiden, South Holland 2300 RC, Netherlands
    Recruiting
    • Eline te Nijenhuis-Noort, MSc, PhD student · Contactl.c.te_nijenhuis@lumc.nl · +31637444875
    • Nienke R. Biermasz, Prof. dr. · Principal investigator
    • Iris C.M. Pelsma, MSc · Sub investigator
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Dec 2027, 29 months after the start.

Of 209 non-industry interventional studies with no phase under Hyperglycemia, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 27. This study's planned 29 months is above that.

Counting every sponsor, half of 226 studies reached it within 14 months; a quarter within 7 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 27, 2026
First posted
Oct 8, 2026
StartActual
Jul 29, 2025
Primary completionEst.
Dec 31, 2027
CompletionEst.
Apr 30, 2028
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07866846
Responsible party
nrbiermasz (Principal Investigator, Leiden University Medical Center) — Principal investigator
First posted
Oct 8, 2026
Start date
Jul 29, 2025
Primary completion
Dec 31, 2027 (estimated)
Completion
Apr 30, 2028 (estimated)
Last update
Oct 8, 2026

Study contacts

Nienke R. Biermasz, Prof. dr.
Contact
n.r.biermasz@lumc.nl
(+31)0715263082
Iris C.M. Pelsma,, MSc
Contact
i.c.m.pelsma@lumc.nl
(+31)715298943

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion